About the Journal

Translational Breast Cancer Research

Aims and Scope

Translational Breast Cancer Research (Transl Breast Cancer Res, TBCR, Online ISSN 2218-6778) launched in November 2019, is an open-access, peer-reviewed journal focusing on translational research in breast cancer.

As a quarterly published journal, the journal seeks to create a platform for researchers and clinicians by presenting pertinent investigations, discussing critical questions relevant to the entire field of breast cancer and aiming to develop new perspectives for all those issues concerned with breast cancer.

As one of the most serious problems of oncology and the leading cause of death of women in many countries, breast cancer is truly a multidisciplinary problem to be handled. Each issue will contain articles dealing with laboratory investigations as well as articles dealing with clinical studies. Translational Breast Cancer Research is indexed and covered by Emerging Sources Citation Index (ESCI).

The journal features original articles, cutting-edge reviews, case reports and some short but thought-provoking articles like editorial commentaries, thus representing a source of valuable, novel information for clinical and basic researchers alike. The entire submission and review process is managed through OJS, an electronic system to increase efficiency and ensure that submissions can be published within a short turnaround period.

Indexing

Translational Breast Cancer Research is indexed and covered by

Information for Authors

TBCR is a member of Committee on Publication Ethics (COPE) and it follows the Committee on Publication Ethics (COPE)'s guidelines and the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal.

Manuscripts submitted must be the original work of the author(s) and must not be published previously or under consideration for publication elsewhere.

Submission Turnaround Time

  • In-house review: 1-3 weeks
  • External peer review: 1-3 months
  • Publication Ahead of Print: within 1 month after being accepted
  • Formal publication: within 1-3 months after being accepted. Original Articles are listed as priority.

Publication Schedule

TBCR follows a quarterly publication model (January, April, July, October).

Open Access Statement

Translational Breast Cancer Research is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.

Free access and usage
Permitted third party reuse is defined by the CC BY-NC-ND 4.0 license. This license allows users to copy and distribute the article, provided:

  • this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way.
  • the user gives appropriate credit (with a link to the formal publication through the relevant DOI) and provides a link to the license but not in an any way implying that the licensor is endorsing the user or the use of the work.
  • no derivatives including remix, transform, or build upon the material was allowed for distribution.
The full details of the license are available at https://creativecommons.org/licenses/by-nc-nd/4.0/

Copyright

For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to TBCR, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

For any inquiry/special circumstance on the copyright, commercial usage or adaptation of TBCR articles, please contact: permissions@amegroups.com

For reprint order, please contact: sales@amegroups.com

Support for Authors to Comply with Funding Body Mandates

We work with authors of research articles supported by funding bodies with open access mandates to ensure that authors can meet their funders’ requirements for public access to research results.

In addition, we offer further support for authors who are required to comply with funding body mandates, including but not limited to:

Editorial Office

Email: tbcr@amegroups.com

Publisher Information

TBCR is published by AME Publishing Company.
Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.


Updated on March 25, 2024